American Academy of Neurology

Gertie Marx Spinal Needle Makes Massive Strides in Reducing PDPH

Retrieved on: 
Wednesday, May 11, 2022
PDPH, Gertie F. Marx, IMD, Bariatrics, American Society of Anesthesiologists, Neck pain, American Academy of Neurology, Research, ASA, Eye, CSF, Patient, Hand, Hearing loss, Society, American Academy, Pediatrics, Phonograph record, Sewing

KATONAH, N.Y., May 11, 2022 /PRNewswire-PRWeb/ -- Post-dural puncture headaches (PDPH) have continually plagued the patient experience, impeding the ability of healthcare providers to offer the highest quality of care possible. As a well-known complication following lumbar punctures and spinal anesthesia, medical institutions have long looked for a solution. Research has shown that both the needle size and needle shape play an integral role in reducing or eliminating the onset of PDPH.

Key Points: 
  • IMD Corp's Gertie Marx atraumatic spinal needle has a less than 1 percent occurrence of PDPH when administered with proper technique.
  • Research has shown that both the needle size and needle shape play an integral role in reducing or eliminating the onset of PDPH.
  • While IMD's pursuit to continually improve their needle design will never cease, the Gertie Marx atraumatic spinal needle has a less than 1 percent occurrence of PDPH when administered with proper technique.
  • Some of the most notable benefits of the Gertie Marx needles include:
    Widest range of needle sizes available: the Gertie Marx spinal needles are perfectly designed for patients of every size from pediatrics through bariatrics.

Cerevel Therapeutics Reports First Quarter 2022 Financial Results and Business Updates

Retrieved on: 
Tuesday, May 10, 2022
COVID-19, Epilepsy, PSL, Forward-looking statement, Brain, Seizure, PANSS, AES, GLOBE, American Academy of Neurology, Lists of Palestinian rocket attacks on Israel, Biotechnology, Schizophrenia International Research Society, Research, Diazepam, Schizophrenia, AAN, Positive and Negative Syndrome Scale, D1, Patient, Patient safety, Pharmacology, Clinical trial, FDA, Conference call, L-DOPA, Anxiety, Total, PAM, SIRS, Marketing, EEG, Screen for child anxiety related disorders, Intention, Congress, GABAA, American Academy, Conference, SEC, ID, Solution, G&A, Terminology, Growth, Positive, Dopamine, Therapy, Pharmaceutical industry, Online gambling, Medical imaging, Residential care, Copper

CAMBRIDGE, Mass., May 10, 2022 (GLOBE NEWSWIRE) -- Cerevel Therapeutics, (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, today reported financial results for the quarter ended March 31, 2022 and provided key pipeline and business updates.

Key Points: 
  • ET
    CAMBRIDGE, Mass., May 10, 2022 (GLOBE NEWSWIRE) -- Cerevel Therapeutics , (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, today reported financial results for the quarter ended March 31, 2022 and provided key pipeline and business updates.
  • Cerevel recently presented Phase 1b emraclidine data at the 2022 Congress of the Schizophrenia International Research Society (SIRS), which took place on April 6-10, 2022.
  • In February 2022, Cerevel announced positive topline results for its Phase 1 trial of darigabat in acute anxiety.
  • ET to discuss its first quarter 2022 financial results and pipeline updates.

Longboard Pharmaceuticals Provides Corporate Update and Reports First Quarter 2022 Financial Results

Retrieved on: 
Thursday, May 5, 2022
COVID-19, G protein-coupled receptor, U.S. Securities and Exchange Commission, Investment, Private Securities Litigation Reform Act, GPCR, Insurance, GLOBE, Lennox–Gastaut syndrome, CNS, American Academy of Neurology, Company, Epilepsy, Judgement, Research, AAN, Dees, Security (finance), Seizure, Clinical trial, FDA, Lists of diseases, Disagreement, Government, R, CB2, Coronavirus, Marketing, Dravet syndrome, CDKL5, American Academy, SEC, G&A, Longboard, Central nervous system, Acquisition, Pharmaceutical industry, Pfizer, IND

LP659, an oral, selective, centrally acting S1P receptor modulator targeting multiple neurological diseases, is currently in IND-enabling studies with IND application submission to the FDA expected in the fourth quarter of 2022.

Key Points: 
  • LP659, an oral, selective, centrally acting S1P receptor modulator targeting multiple neurological diseases, is currently in IND-enabling studies with IND application submission to the FDA expected in the fourth quarter of 2022.
  • In March 2022, Dr. Randall Kaye joined the Company as Chief Medical Officer.
  • First Quarter 2022 Financial Results:
    At March 31, 2022, Longboards cash, cash equivalents and short-term investments were approximately $96.1 million.
  • Longboard disclaims any intent or obligation to update these forward-looking statements, other than as may be required under applicable law.

Synchron Announces Enrollment of First Patient in U.S. Endovascular Brain Computer Interface Study COMMAND in Patients With Severe Paralysis

Retrieved on: 
Wednesday, May 4, 2022
Health, Clinical Trials, Medical Devices, Silicon, MNP, Epilepsy, COMMAND, Brain, University, Twitter, SWITCH, American Academy of Neurology, Death, Stroke, Nervous system, MS, NIH, Safety, Motor cortex, Paralysis, Depression, Patient, EFS, Clinical trial, FDA, National, Disability, Mount Sinai Hospital, IDE, American Academy, Conference, BCI, CEO, Technology, Skull, Hypertension, Medical device, Pharmaceutical industry, Beckman Coulter, Neurology, MD, Stent-electrode recording array

Synchron , an endovascular brain-computer (BCI) interface company, today announced the enrollment of the first patient in the US clinical trial, COMMAND, for patients with severe paralysis, at Mount Sinai Hospital in New York.

Key Points: 
  • Synchron , an endovascular brain-computer (BCI) interface company, today announced the enrollment of the first patient in the US clinical trial, COMMAND, for patients with severe paralysis, at Mount Sinai Hospital in New York.
  • The Stentrode is implanted to the motor cortex of the brain through the jugular vein in a minimally-invasive procedure.
  • The COMMAND study progresses Synchrons technology development through the feasibility stage as we prepare for our pivotal trial.
  • Synchron, a brain interface platform company, is a leader in the field of implantable neural interface technology.

Verana Health to Present Machine Learning and Geographic Atrophy Research at ARVO 2022 Annual Meeting

Retrieved on: 
Thursday, April 28, 2022
Confederation of Laboratories for Artificial Intelligence Research in Europe, Solution, American Urological Association, Medicine, American Academy, IRIS, Association, Patient, Severe cognitive impairment, Annual general meeting, PDT, Quality of life, Association for Research in Vision and Ophthalmology, HCP, American Academy of Neurology, Health, AMD, Diagnosis, 2021 Essex County Council election, Multimedia, Data management, Geographic atrophy, American Academy of Ophthalmology, ARVO, HCPS, Medical imaging, Pharmaceutical industry, Research, Ophthalmology

SAN FRANCISCO, April 28, 2022 /PRNewswire/ -- Verana Health®—a digital health data company elevating quality in real-world data—today announced three abstracts are to be presented at the Association for Research in Vision and Ophthalmology's (ARVO) 2022 Annual Meeting, which will be held in Denver May 1-4.

Key Points: 
  • The IRIS Registrypowered by Verana Health's VeraQ population health data engineis the nation's first and the world's largest electronic health record-based registry on comprehensive eye disease and conditions.
  • The three research abstracts being presented at ARVO demonstrate Verana Health's commitment to collaborating with life sciences companies to uncover new insights from its exclusive real-world data network of more than 20,000 healthcare providers.
  • Verana Health is a digital health company elevating quality in real-world data.
  • Using its clinician-informed and artificial intelligence-enhanced VeraQpopulation health data engine, Verana Health transforms structured and unstructured healthcare data into curated, disease-specific data modules, Qdata.

ProMIS Neurosciences Reports New Milestones in Potential Therapeutic Approaches for Amyotrophic Lateral Sclerosis (ALS)

Retrieved on: 
Thursday, April 28, 2022
Antibody, Epitope, Neurodegeneration, ALS, FTD, Intention, Motor neuron, American Academy of Neurology, CMO, TSX, Spinal cord, American Academy, PD, Patient, GLOBE, RACK1, Cell, AD, Amyotrophic lateral sclerosis, PROMIS, Company, Toronto Stock Exchange, Therapy, University of California, San Diego Performance-Based Skills Assessment, Disease, Brain, Neuron, University, PMN, Survival, Neuroscience, Pharmaceutical industry, Vaccine, Neurology

Recent data generated by two independent sources have now provided additional support for the therapeutic potential of PMN267.

Key Points: 
  • Recent data generated by two independent sources have now provided additional support for the therapeutic potential of PMN267.
  • Dr. Larry Altstiel, ProMIS CMO, said this is promising work to be moved forward as rapidly as possible to address the tragic human disease ALS.
  • ProMIS also notes the progress made in targeting another ALS/FTD target called RACK1 (receptor for activated C kinase 1).
  • ProMIS Neurosciences, Inc. is a development stage biotechnology company focused on discovering and developing therapeutics selectively targeting toxic misfolded oligomers implicated in the development and progression of neurodegenerative diseases, in particular Alzheimers disease (AD), amyotrophic lateral sclerosis (ALS) and Parkinsons disease (PD).

Study of More Than 18,000 Patients Finds Exome Sequencing Delivers Higher Diagnostic Rates for Autism Spectrum Disorders

Retrieved on: 
Tuesday, April 26, 2022
American Academy of Neurology, Genetic testing, Fragile X syndrome, FMR1, LLC, CDC, Genetics, Lists of diseases, Autism, Simons Foundation Autism Research Initiative, Research, Genomics, Database, Diagnosis, Data, National, Patient, Cancer, Standard of care, Gene, AAN, CGH, American Academy, Multimedia, SFARI, ASD, GeneDx, Vaccine, Medical imaging

GAITHERSBURG, Md., April 26, 2022 /PRNewswire/ -- GeneDx, LLC, a leader in genomic analysis, today unveiled new data demonstrating positive outcomes of exome analysis for individuals with autism spectrum disorders (ASD), supporting the use of a broader genetic testing approach to diagnose ASD. This retrospective study is one of the few to examine the genetic basis of autism and current guidelines around screening and testing and is among the largest studies of genetic testing in ASD.

Key Points: 
  • Results demonstrate that exome analysis provides higher diagnostic rates of 7.9-21.0% and shorter diagnosis wait times than traditional testing strategies, including Fragile X (FMR1) and array CGH.
  • Importantly, this study revealed a high number of emerging genes not previously connected to autism.
  • This further supports the use of exome analysis for the discovery and understanding of genes associated with ASD.
  • We will work tirelessly to help ensure all patients have access to exome, which is a more definitive tool."

American Academy of Neurology (AAN 2022) – Braintale Showcases Together with Minoryx Data From Its Biomarker Platform for Disease and Treatment Monitoring of X-linked Adrenoleukodystrophy and Strengthens Collaboration

Retrieved on: 
Monday, April 25, 2022
Hardware, Data Management, Other Health, Technology, Pharmaceutical, Mental Health, Medical Devices, Hospitals, Clinical Trials, Science, Biotechnology, Software, Other Science, Health, Research, ALS, Ageing, CEO, Adrenoleukodystrophy, American Academy of Neurology, Neurology, European Medical Writers Association, Adult, MDR, ISO, Research, Medtech, Trauma, Brain, AMN, PPAR, Death, Patient, Biomarker, Inflammation, Amyotrophic lateral sclerosis, X-ALD, Neuroscience, Degenerative disease, Female, Neurodegeneration, Conditional sentence, Assistance, AAN, American Academy, HIV disease progression rates, White matter, Cardiac arrest, Physician, NEXUS, Decision-making, Male, Disease, Partnership, Risk, Neurological disorder, CALD, Therapy, Medical imaging, Medical device, Pharmaceutical industry

Accordingly, Braintale has been developing, since its inception in 2018, non-invasive, accessible, effective and clinically validated measurement and prediction tools for physicians treating patients suffering from brain diseases.

Key Points: 
  • Accordingly, Braintale has been developing, since its inception in 2018, non-invasive, accessible, effective and clinically validated measurement and prediction tools for physicians treating patients suffering from brain diseases.
  • The Braintale platform includes AI-processed CE-marked digital solutions, deployed across three modules.
  • On the occasion of the American Academy of Neurology, Braintale and Minoryx jointly presented additional results of a multicenter sub-study from the ADVANCE trial.
  • With noninvasive, sensitive and reliable measurements of white matter microstructure alterations, Braintale offers a digital biomarkers platform to support clinical decision-making.

Xalud Therapeutics Adds Amy Chappell, M.D., as a Strategic Advisor

Retrieved on: 
Monday, April 25, 2022
Indiana University School of Medicine, American Academy of Neurology, Pain, Biotechnology, DNA, MBA, Migraine, Doctor of Philosophy, Antioch College, GLOBE, Eli Lilly and Company, Interleukin, Inflammation, University School, Neuroscience, Immune system, Company, Biology, Retirement, American Academy, Eli Lilly, FAAN, Epilepsy, Therapy, Homeostasis, Pharmaceutical industry

NEW YORK, April 25, 2022 (GLOBE NEWSWIRE) -- Xalud Therapeutics, a clinical-stage biotechnology company developing DNA-delivered therapeutics, today announced the appointment of Amy Chappell, M.D., as an independent strategic advisor.

Key Points: 
  • NEW YORK, April 25, 2022 (GLOBE NEWSWIRE) -- Xalud Therapeutics, a clinical-stage biotechnology company developing DNA-delivered therapeutics, today announced the appointment of Amy Chappell, M.D., as an independent strategic advisor.
  • Dr. Chappell will work with Xalud senior management and other advisors to provide strategic input and direction for Xaluds R&D programs, including XT-150, a nonviral DNA-based delivery platform with potential for a broad number of indications.
  • I believe that Xaluds DNA-delivered therapeutic approach holds significant promise for treating a range of inflammatory disorders, Dr. Chappell noted.
  • Xalud Therapeutics is a biotechnology company developing a DNA-delivered therapy platform to treat pathologic inflammation through immune modulation.

Quanterix Granted Breakthrough Device Designation from U.S. FDA for NfL Test for Multiple Sclerosis

Retrieved on: 
Friday, April 22, 2022
Research, Medical Devices, FDA, Clinical Trials, Biotechnology, Pharmaceutical, Health, Science, Oncology, Other Science, News, RRMS, Health, American Academy of Neurology, University of Basel, Minuteman Library Network, Prognosis, U.S. Securities and Exchange Commission, The Lancet, Longevity, University Hospital of Basel, Annual general meeting, Population, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, NASDAQ, Multiple sclerosis research, Intention, Research, Diagnosis, Food, Science, Private Securities Litigation Reform Act, Serum, Program, Risk, Patient, Infection, Inflammation, Sclerosis, Corporation, Review, Founder, The Ottawa Hospital, Technology, Plasma, AFL, Forward-looking statement, AAN, Cardiology, American Academy, FDA, Disease, Quality of life, MS, University, Multiple sclerosis, PPH, Medical device, Medical imaging, Pharmaceutical industry, Neurology

The FDAs Breakthrough Device designation is granted to products that have the potential to offer more effective diagnosis or treatment of life-threatening diseases with an unmet medical need.

Key Points: 
  • The FDAs Breakthrough Device designation is granted to products that have the potential to offer more effective diagnosis or treatment of life-threatening diseases with an unmet medical need.
  • However, Breakthrough Device designation does not guarantee that the FDA review and approval process will be shortened or that an application will be approved.
  • Obtaining FDA breakthrough device designation for our plasma NfL MS test was a key objective for 2022.
  • We are pleased to have the opportunity to work with the FDA to help advance the Quanterix Simoa NfL test towards regulatory approval.